We evaluated the methylation status of p15 gene in a series of 65 patients with newly diagnosed acute promyelocytic leukemia (APL) receiving homogeneous treatment. Moreover, in 32 of them, the methylation status of p15 gene was correlated to the p15 m-RNA expression. In total, 31 patients had no p15 methylation (U group). An abnormal methylation pattern was found in 34 patients: in seven of these patients only methylated DNA was detected (M group), while in the remaining 27 patients (M/U group), both methylated and unmethylated DNA were amplified. Patients from M group showed a higher incidence of relapses and a lower disease-free survival (DSF) with respect to patients from U and M/U groups (29, 64 and 79% at 5 years for M, U/M and U patients, respectively, P ¼ 0.03), while p15 methylation had no impact on overall survival. The p15 expression was detectable in all patients with unmethylated DNA, in none of patients with fully methylated DNA and in 60% of patients with partially methylated DNA. The DFS estimate at 5 years for p15-negative patients was significantly lower than that of p15-positive patients (P ¼ 0.03). These data confirm that the presence of p15 methylation negatively influences the prognosis of APL, mainly when it represses the p15 gene transcription.
Introduction
The cyclin-dependent kinase (CDK) family of enzymes is responsible for the orderly progression of cells through the various phases of the cell cycle. CDKs are mainly regulated by two families of proteins: the CIP1/WAF1 family of CDK inhibitors (CDKIs) and the INK4 family of CDKIs. 1 In particular, p15 INK4B (p15) is specific for CDK4 and CDK6, and binds these kinases both in their inactive and active heterodimeric forms, 2 leading to cell cycle arrest in response to exogenous antiproliferative stimuli. 3 The function of CDKIs in the irreversible growth arrest associated with terminal differentiation has been only partially elucidated. For example, the cell cycle exit during terminal erythroid differentiation is associated with the accumulation of p27 Kip1 , 4 while p15 and p21 WAF1 are upregulated during the granulocytic and the monocytic differentiation. 5, 6 By analyzing p15 expression along normal hematopoiesis, we have shown that this CDKI undetectable in normal CD34+ cells is upregulated when hematopoietic progenitors undergo myeloid differentiation, and p15 m-RNA becomes detectable when the vast majority of maturing cells are promyelocytes. 7 These findings suggest that p15 has an important role in the regulation of the proliferative activity of promyelocytes, the most differentiated granulocytic elements still able to undergo cell division. In this respect, it is interesting to note that a high proportion of patients with acute myeloid leukemia (AMa) and myelodysplastic syndromes show an abnormal methylation of the p15 gene promoter. 8 Acute promyelocytic leukemia (APL) is characterized by the presence of the oncogenic transcription factor PML-RARa in tumor cells. 9 Recently, Di Croce et al 10 showed that the PML-RAR fusion protein is able to recruit DNA methyltransferases on the CpG islands of the promoter of a putative target gene, the retinoic acid (RA) receptor RARb2, inducing in APL cells hypermethylation and silencing of this gene. Moreover, Chim et al 11 reported a high incidence of p15 methylation in patients with APL and demonstrated that the 5-year disease-free survival (DSF) of patients with abnormal methylation of p15 was significantly inferior to that of patients without p15 methylation. However, this study was carried out on 26 patients heterogeneously treated and their reported survival was considerably inferior to that expected for patients receiving modern RA plus chemotherapy treatments. 12 Finally, the authors did not investigate whether the abnormal methylation of p15 gene resulted in the loss of the p15 expression.
In this study, we evaluated the methylation status of p15 in a series of 65 patients with newly diagnosed APL receiving homogeneous treatment according to the Italian AIDA protocol. 13 Moreover, in a part of them, the methylation status of p15 was correlated to the RNA expression of p15, estimated by semiquantitative RT-PCR. Our results confirm the prognostic relevance of p15 methylation status, but, in addition, identify p15 expression as a novel criterion to better identify APL patients at increased risk of relapse.
Materials and methods

Patients
We studied bone marrow (BM) samples obtained from 65 not consecutive patients (40 males and 25 females) with de novo APL, admitted to Hematology Departments of La Sapienza University and of Catholic University of Rome between November 1992 and March 2001. The unique criterion for the patient inclusion in the study was the availability of DNA and RNA samples. The median age at diagnosis was 38 years (range 1-76 years). All cases were diagnosed as AML FrenchAmerican-British (FAB) M3 or M3 variant by morphocytochemical criteria.
14 In all cases, karyotypic and/or molecular evidence of the t(15;17) was present, as a mandatory prerequisite for study enrollment. The PML/RARa breakpoint type was determined in 61 patients. Of these, 38 showed Bcr1, one patient a Bcr2 and 22 patients Bcr3 isoform. In all, 44 patients were treated according to standard AIDA protocol as reported 13 and 21 patients received a slightly modified treatment referred to as AIDA 2000. The latter consisted, following the same induction, of a risk-adapted consolidation including the Pethema scheme 15 for patients in the low-and intermediaterisk categories, and in the original AIDA consolidation scheme for high-risk patients. The definition of risk categories has been reported elsewhere. 15 All patients in the AIDA 2000 received, in addition, oral all trans-retinoic acid (ATRA) for 15 days in combination with consolidation chemotherapy during each of the three cycles. Complete response (CR) was defined as the reconstitution of normal BM cellularity with less than 5% leukemic promyelocytes, together with peripheral blood cell count of granulocytes 41500/ml and platelets 4100 000/ml.
DNA methylation assay
BM samples were diluted 1:5 with Iscove's modified Dulbecco's medium (IMDM; Hyclone, UK) and centrifuged over FicollHypaque (density 1077; Pharmacia, Uppsala, Sweden) to isolate the mononuclear cell fraction. More than 95% of the obtained cells were blasts and pathological promyelocytes at morphologic examination. Genomic DNA was isolated from each sample using DNAzol (Invitrogen, Paisley, UK), resuspended in 50 ml NaOH 8 mM and incubated overnight at 371C.
Methylation-specific PCR (MS-PCR) was carried out according to the method originally described by Herman et al 16 DNA (1 mg) was denatured with NaOH 2 M (final concentration 0.2 M) for 10 min at 371C, after addition of 1 mg of salmon sperm DNA (Sigma, St Louis, MO, USA) in each sample, as a carrier. Then, 15 ml of 10 mM hydroquinone and 260 ml of 3 M sodium bisulfite (pH 5, both purchased from Sigma, St Louis, MO) were added. After mixing, samples were incubated under mineral oil at 501C for 16 h. Modified DNA was purified using Wizard DNA cleanup purification resin, according to the manufacturer's protocol (Promega, Madison, WI, USA) and finally eluted into 50 ml of water. MgCl 2 ), in a final volume of 50 ml. We used DNA extracted from blood of a healthy donor by standard phenol/chloroform method, as unmethylated control, Raji cell line DNA as methylated control and water as negative control. PCR products were loaded on 2.5% agarose gels, stained with ethidium bromide and visualized under ultraviolet illumination. The size of the PCR products was 154 bp for unmethylated and 148 bp for methylated reaction.
To evaluate the sensitivity of MS-PCR, 1 mg of DNA of Raji cell line and normal donor were diluted serially (in serial 10-fold dilutions) with normal DNA and water, respectively, modified by bisulfite and amplified with primers for methylated (Raji cell line DNA) and unmethylated (normal DNA) p15. Dilution of the Raji cell line DNA showed that the sensitivity of MS-PCR for methylated p15 was 1 Â 10
À5
. Dilution of normal DNA showed that the sensitivity of MS-PCR for unmethylated p15 was 1 Â 10 À4 . These results are concordant with those of previously reported studies on MS-PCR and/or p15 gene methylation in AML. 8, 11 RT-PCR analysis RNA was extracted using TRIzol reagent (Invitrogen, Paisley, UK), following the manufacturer's instructions. Total RNA was eluted in RNAse-free water, and treated with RQ1 RNAse-free DNAse (1 U/ml) (Promega, Madison, WI, USA) at 371C for 15 min, to eliminate DNA contamination. RNA was then extracted using standard phenol/chloroform/isoamyl alcohol extraction. First-strand cDNA was synthesized by incubating 0.5-1 mg of RNA at 421C for 50 min in a final volume of 20 ml containing RT buffer 1 Â (50 mM Tris-HCl pH 8. 0 for b-actin, with an expected PCR product of 234 bp. b-Actin was used in each PCR reaction as internal control according to the method previously described. 7, 18 BM mononuclear cells and water were used, respectively, as positive and negative controls. PCR products were separated in 2% agarose gel and transferred onto nylon membranes (Amersham, Arlington Heights, IL, USA), and standard hybridization was performed using a p15-specific DNA probe. The probes used in the hybridization procedure were labeled with [a-32 P]dCTP (3000 mCi/mmol; ICN,) by the RadPrime labeling kit (Invitrogen, Paisley, UK). Densitometric analysis was performed for all the samples using the Molecular Imager (Biorad, Hercules, CA, USA).
In order to normalize the p15 transcript levels, the density of the p15 band was divided by the band density of b-actin. This strategy allowed us to compare the relative p15 transcript levels in different specimens. Moreover, the b-actin amplification served as control for the p15 RT-PCR reaction, to further verify the integrity and amplificability of RNAs as well as the efficiency of the reverse transcription step. The levels of p15 expression (density of p15 band/density of b-actin band) are given as arbitrary units. 
Statistical analysis
Results
Methylation state of the p15 promoter region and correlation to the m-RNA expression in APL patients
Clinical and laboratory characteristics at the time of diagnosis in the 65 patients affected by de novo APL are detailed in Table 1 .
The results of MS-PCR in DNA samples showed the absence of methylation in the p15 promoter region in 31 (48%; U group) out of 65 patients investigated (Table 1) . On the contrary, 34 (52%) patients had abnormal p15 methylation, as demonstrated by amplification with the p15 methylated reaction. In seven of these patients (11%; M group), no DNA could be amplified by the p15 unmethylated reaction, showing a complete methylation of both alleles in the examined region of the p15 promoter (Table 1 ). In the remaining 27 patients (41%, M/U group), both methylated and unmethylated DNA could be amplified (Table 1 , Figure 1 ). Assuming that this finding might have a functional significance, we explored in 32 unselected patients (seven from the M group, 15 from the U group and 10 from the M/U group) the expression of p15 m-RNA by semiquantitative RT-PCR ( Figure 2 ). We found that none of the M patients expressed p15, while all the U patients and six (60%) of the M/U patients did (Table 2) . Thus, the p15 gene silencing was significantly more frequent in the M group in comparison with either the U or the M/U groups (Po0.001, Table 2 ). In addition, we observed in U patients a trend towards higher p15 expression levels as compared to M/U patients, as evaluated by densitometric analysis of the amplified bands (the median value of p15/bactin ratio was 0.6 and 0.31, respectively, P ¼ 0.0032; Table 2 ).
Clinical and laboratory features at diagnosis, and treatment outcome according to the p15 promoter methylation status
Clinical and laboratory features at diagnosis in patients with different patterns of p15 promoter methylation are shown in Table 1 . The three groups of patients (U, M, M/U) did not differ in sex and age distribution, in the level of white blood cell (WBC) and platelet count, in the entity of BM infiltration by leukemic cells, nor in the PML/RARa junction type ( Table 1 ). The different groups of patients were also analyzed according to the presence of an initial WBC count over than 10 Â 10 9 /l, a largely considered bad prognostic indicator in APL. 19, 20 Nevertheless, the three patient groups did not differ for this variable (P ¼ 0.71, Table 1 ). In all, 44 patients (68%) were treated according to the standard AIDA chemotherapy protocol 13 and 20 patients (32%) entered in the AIDA 2000 protocol: these two treatments induced in our series of patients similar OS (P ¼ 0.55) and DFS (P ¼ 0.6) rates. Complete remission after induction therapy was obtained in 61 patients (94%); two patients died early of cerebral hemorrhage and one patient was lost to followup before BM examination after completing the induction phase of the protocol. The median follow-up was 22.6 months (range 0.1-95.2). In total, 14 patients relapsed (11 enrolled in the AIDA protocol and three enrolled in the AIDA 2000 protocol; P ¼ 0.51) and 10 patients died (eight from the AIDA group and two from the AIDA 2000 group; P ¼ 0.71). Details on treatment, ATRA syndrome, relapse incidence and mortality for APL patients, grouped according to their p15 methylation status are Table 3 . Patients with different p15 methylation states were similarly distributed between the two therapy protocols AIDA or AIDA 2000 (P ¼ 0.41) and the rate of CR achievement was similarly high in the three groups of patients. No difference was found in the incidence of ATRA syndrome 21 (P ¼ 0.30). However, among patients achieving CR, a higher relapse rate was observed in M patients as compared to either U patients and M/U patients. In fact, 71% of the patients belonging to the former group relapsed, compared to 14% of patients belonging to the U group and 18% of patients belonging to the M/U group (P ¼ 0.0056 and 0.013, respectively). No difference was found in the mortality rate among the different groups of patients (P ¼ 0.56, Table 3 ). At multivariate analysis, the detection of complete p15 methylation status was confirmed as an independent poor prognosis factor. In fact, the M group of patients showed an increased relapse risk as compared either to the M/U group (hazard ratio 3.67, 95% CI 1.0-12.7, P ¼ 0.040) or to the U group (hazard ratio 5.51, 95% CI 1.4-20.6, P ¼ 0.01), not influenced by all the other tested variables (age, sex, WBC and platelet counts, treatment, ATRA syndrome incidence and PML/RARa breakpoint type). We analyzed DFS according to the methylation status of p15, in the 62 patients who achieved CR. Estimated DFS rate at 5 years were 29, 64 and 79% for M, M/U and U patients, respectively (log-rank test: P ¼ 0.03, Figure 3a) , with a median DSF time of 17 months for patients belonging to the first group. The actuarial OS at 5 years, calculated for all 65 patients, was 69, 71 and 85% for M, U/M and U groups, respectively (log-rank test: P ¼ 0.77, Figure 3b ).
Clinical outcome and p15 m-RNA expression
Clinical outcome according to the p15 m-RNA expression was analyzed in 32 patients. These patients included all the seven patients from the M group, 10 patients from the U/M group and 15 patients from the U group. Clinical and laboratory features at diagnosis of patients from the U and U/M groups investigated for p15 expression were similar to those of the respective entire series of patients with unmethylated or unmethylated/methylated DNA. In particular, no differences were found in the sex Table 2 Analysis of p15 expression in 32 patients with APL No of patients (%) 2 (29%) 4 (15%) 4 (13%) 0.56 a The incidences of ATRA syndrome, complete remission achievement rate and the relapse rate were calculated by excluding from the analysis three patients with unmethylated DNA: two of them died during the induction therapy and one patient was lost at follow-up before BM evaluation after induction therapy. The number of deaths was calculated by excluding the patient lost at follow-up. Abbreviations as in Tables 1 and 2 .
p15gene methylation and p15 expression in APL L Teofili et al distribution, WBC count, platelet count, BM leukemic cell infiltration, PML/RARa junction type, and incidence of ATRA syndrome. The relapse rate in U patients or M/U patients investigated for p15 expression was similar to that observed in the respective entire group (20 vs 14% in patients from the U group, P ¼ 0.66; 30 vs 18%, in patients from the U/M group, P ¼ 0.67). Similarly, the mortality observed in patients investigated for p15 expression was comparable to that of the entire respective group (7 vs 13% in patients from the U group, P ¼ 1; 20 vs 15%, in patients from the U/M group, P ¼ 0.65). Among patients investigated for p15 expression, 11 patients were p15 negative and 21 patients were p15 positive. In the whole group, 11 patients relapsed and five patients died. The relapse rate was significantly higher in p15-negative than in p15-positive patients (7/11 vs 4/21, P ¼ 0.019), whereas the number of deaths was comparable between the two groups (3 vs 2, P ¼ 0.29). Accordingly, the DFS estimate at 5 years for p15-negative patients was significantly lower than that of p15-positive patients (24 and 66%, respectively, log-rank test: P ¼ 0.03) with a median DFS time of 24.9 months for p15-negative patients (Figure 4a ). On the contrary, no differences were observed in the OS (74 and 85% in p15-negative and p15-positive patients, respectively, log-rank test: P ¼ 0.24, Figure 4b ).
Discussion
DNA hypermethylation has recently emerged as one of the most frequent changes occurring in hematopoietic neoplasms. Since methylation and transcriptional status are inversely correlated, the hypermethylation of genes involved in cell cycle control and apoptosis might have a pathogenetic role in the development of cancer. A number of studies have reported a high incidence of p15 hypermethylation in all FAB subtypes of AMLs (reviewed by Issa et al
22
)
. In our study, carried out on the largest series of APL patients to date investigated for p15 methylation, we observed p15 hypermethylation in 52% of patients. In a previous study, Chim et al 11 found hypermethylation of the p15 promoter in 73% out of 26 APL patients. This discrepancy can be due at least in part to the smaller number of patients examined. Furthermore, the series described in that study substantially differed from ours for the high relapse rate. In fact, the 5 year DFS of patients investigated by Chim et al 11 was considerably lower than that usually reported in the literature for APL, 12 suggesting that a poor prognosis population was selected in the study, which in turn might explain their high incidence of p15 methylation.
In our study, we detected the presence of methylated DNA bands together with unmethylated DNA bands in a high proportion of patients. Although similar findings have been otherwise considered as the result of the contamination by normal cells, 23 in the present study this does not appear to be the case, because of the high purity of leukemic cell population assayed in each patient (more than 95%). Actually, by cloning and sequencing individual alleles from fresh leukemic blasts and from leukemic cell line, Cameron et al 24 demonstrated that the exact location of methylated CpG sites is variable between alleles from each leukemic sample, and that not all alleles within the same sample could be involved by the abnormal methylation process. As a consequence, the detection of methylated p15 DNA in each cell sample does not necessarily imply that p15 gene transcription is abolished. By investigating the expression of p15 in our series, we found that all patients with fully methylated DNA did not express p15, while all patients presenting fully unmethylated DNA did. Interestingly, among patients showing both methylated and unmethylated DNA, p15 expression was inconstant. A possible explanation of this finding could be that our DNA methylation assay examines only a restricted frame of the p15 promoter and it does not exclude the presence of abnormal methylation, able to repress the gene transcription, in other promoter regions not included in the investigated DNA sequence. This observation confirms previous data of Preisler et al, 25 which shows that the presence of p15 methylation in leukemic cells is not always associated with the lack of p15 nor is the p15 expression always observed in the absence of methylation. Interestingly, we found that a poor clinical outcome was associated both with the absence of unmethylated DNA and with the absence of p15 expression, as indicated by the reduced DSF in the M group of patients and in p15-negative patients. Thus, our observations suggest that hypermethylation of p15 promoter per se is not the critical factor inducing an increased relapse risk, and that abnormal methylation confers poor prognosis only when it results in the absence of p15 expression. The analysis of methylation of large DNA sequences of p15 promoter could help to identify those patients not expressing p15, although they appear only partially methylated at our MS-PCR.
One clinical peculiarity of APL is its high sensitivity to the association of ATRA and anthracycline-based chemotherapy. 12, 13, 15 In addition, the recent introduction of alternative treatment modalities, such as arsenic trioxide or anti-CD33 monoclonal antibody, further allow to frequently rescue into durable second CR a large proportion of patients who relapse after frontline therapy. 12 A number of prognostic indicators detectable at diagnosis, such as initial leukocyte count or the CD56 expression on leukemic cells 19, 20 can be used to better identify those APL patients who may benefit from more intensive consolidation therapy after remission induction. In this respect, the promoter methylation status of the p15 gene has been previously indicated as an additional prognostic indicator. 11 Nevertheless, our observations clearly indicate that the transcriptional status more than the methylation pattern of p15 gene can represent a novel additional tool for improved patient stratification and for better designing risk-adapted therapy.
